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ABSTRACT  26 
BACKGROUND AND AIMS: Low-grade inflammation is associated with fat mass in 27 
overweight. Whether this association exists in lean persons is unknown.  28 
Aimes were to investigate associations between anthropometric measures of fat distribution 29 
and fat mass (% and kg) assessed by bioelectrical impedance analysis (BIA). Furthermore we 30 
wanted to investigate the relationship between fat mass and markers of insulin resistance, 31 
inflammation, and lipids in healthy subjects in different BMI categories.  32 
METHODS: We compared 47 healthy overweight adults (BMI 26-40kg/m
2
) and 40 lean 33 
(BMI 17-25kg/m
2
) matched for age and sex. Waist- and hip circumferences, waist-to-hip 34 
ratio, waist-to-height ratio and triceps skinfold were used to evaluate fat distribution. BIA was 35 
used to estimate fat mass (% and kg). Markers of insulin resistance, lipids, inflammation and 36 
adipokines were measured.   37 
RESULTS: Hip circumference was associated (P<0.01) with BIA-assessed fat mass (%) in 38 
both groups (lean: regression coefficient B=0.4; overweight: B=0.5). An increase in hip 39 
circumference in all tertiles was associated with higher plasma levels of leptin, CRP and C-40 
peptide in both groups. 41 
CONCLUSIONS: Fat mass may play a role in low-grade inflammation also in subjects 42 
within the normal range of BMI. Hip circumference may be a surrogate measure for fat mass 43 
in subjects in different BMI categories, and may be useful for identification of people with 44 
risk of developing overweight-related chronic diseases.  45 
  46 










The prevalence of overweight and obesity has increased dramatically worldwide (1).  56 
Frequently associated health risks are insulin resistance, elevated blood pressure and 57 
hypercholesterolemia, which may lead to type 2 diabetes and cardiovascular disease (2). The 58 
most important determinant of these problems is not the increased body mass per se, but 59 
rather the total amount of fat, its distribution in the body and metabolic factors that are related 60 
to fat tissue mass (3). Fat tissue is an active endocrine organ releasing adipokines (leptin, 61 
adiponectin, resistin) and inflammatory factors, e,g, interleukin (IL) –6 (4). These mediators 62 
modify carbohydrate- and lipid metabolism and contribute to insulin resistance, 63 
hyperlipidemia and inflammatory processes (5). It is well known that inflammatory markers 64 
are associated with fat mass in overweight and obese subjects (6), but this relation between fat 65 
mass and inflammatory markers in lean subjects is not well documented (7). 66 
Several methods are used to measure the amount of fat in adults. One of the most 67 
accurate methods is Dual-energy X-ray absorptiometry (DXA) (7), but measuring fat this way 68 
is costly and not readily available in clinical practice. Bioelectrical impedance analysis (BIA) 69 
is more available and widely used outside hospitals (8), and an objective, quick and non-70 
invasive method for assessment of fat and fat free mass (9, 10). Validation studies of BIA 71 
against DXA showed that BIA is an adequate tool for prediction of fat (%) in healthy 72 
populations (11). The most common population-level measure is probably estimation of body 73 
mass index (BMI) (12). Whether BMI is a good marker to define obesity and health status is 74 
debated (13). Studies have shown that BMI fails to differentiate between elevated body fat 75 
and increased lean mass, especially in subjects with a BMI < 30 kg/m
2
, a frequent cut-off for 76 
obesity (12). Other anthropometric measures, such as waist circumference, hip circumference, 77 
waist-to-hip ratio, waist-to-height ratio and triceps skinfold, are often used to determine fat 78 
distribution (13, 14). Like BMI all these measures are just proxies of fat mass, but may predict 79 
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adverse outcomes (14). The INTERHEART Study showed that increasing waist-to-hip ratio 80 
was a predictor of myocardial infarction in subjects with BMI < 20 kg/m
2
, subjects with 81 
recommended weight (BMI 20-25 kg/m
2
), as well as in overweight and obese subjects (BMI 82 
> 25 kg/m
2
) (15). Thus in further studies of the role of adipokines and inflammation in the 83 
development of metabolic disorders it will be of interest to investigate if fat mass estimated by 84 
anthropometric measures can predict levels of inflammatory markers not only in overweight, 85 
but also in lean subjects. Our primary study aim was therefore to determine if any of the 86 
frequently used anthropometric measures of fat mass (BMI, waist circumference, waist-to-hip 87 
ratio, waist-to-height ratio and triceps skinfold) were associated with BIA-measured fat mass. 88 
Furthermore we wanted to investigate the relationship between the anthropometric measure 89 
with the strongest correlation with BIA, and adipokines, inflammatory markers, markers of 90 
















MATERIALS AND METHODS  106 
Subjects 107 
The study population included 47 overweight and 40 lean healthy adult volunteers 108 
(M:59/F:28). The overweight group consisted of subjects available for baseline analysis in a 109 
contemporary intervention trial performed in 2009. They were approached through mass 110 
media and selected in accordance with the following inclusion criteria: waist circumference > 111 
94 cm (men), > 80 cm (women), and BMI 26 - 40 kg/m
2
. Exclusion criteria were type 2 112 
diabetes, kidney, liver, gall bladder, coronary, endocrine or rheumatoid disease, any 113 
malignancy the last 5 years, hypertension (160/100 mmHg), pregnancy and lactation. 114 
Regular use of anti-inflammatory, lipid lowering and antihypertensive medication was not 115 
permitted. In 2010, a reference group of lean subjects was recruited in the same way as the 116 
overweight subjects. Inclusion criteria were: waist circumference ≤ 94 cm (men), ≤ 80 cm 117 
(women), BMI 17-25 kg/m
2
 and age 18-70 years.  Exclusion criteria were the same as for the 118 
overweight group. The study groups were matched on age and sex. All subjects were 119 
instructed to refrain from vigorous physical activity and alcohol the day before the study visit. 120 
The study protocol complied with the principles laid down in the Declaration of Helsinki, and 121 
approved by the Regional Committee for Medical and Health Research Ethics. Written 122 
informed consent was obtained from all participants.  123 
 124 
Laboratory methods 125 
Venous blood samples were collected after an overnight fast (≥12 hours), between 8.00-10.00 126 
a.m. Serum was obtained from silica gel tubes (Becton Dickinson vacutainer, Plymouth, Great 127 
Britain) and kept on ice, centrifuged (1500 g for 12 minutes), aliquoted and stored at -80ºC 128 
until further analyses (inflammatory markers), or kept in room temperature (for standard 129 
clinical chemistry) for at least 30 minutes, until centrifugation at 1500 g for 12 minutes and 130 
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immediately prepared for subsequent analysis. Plasma was obtained from EDTA tubes 131 
(Becton Dickinson), kept on ice and centrifuged (2000 g, 4°C, 10 minutes) within 15 minutes. 132 
Plasma samples were aliquoted and stored at -80 ºC until further analysis. 133 
Serum leptin, serum adiponectin, serum resistin, plasma IL-6, and plasma insulin-like 134 
growth factor-1 (IGF-1) levels were measured by enzyme immunoassays from R&D Systems 135 
(Minneapolis, USA) according the manufacturer’s instructions. All analyses were performed in 136 
duplicates. The coefficients of variation for intra-assay and inter-assay variability were <5% 137 
and <10%, respectively, for all analyses. Standard blood chemistry and lipid parameters were 138 
measured in serum or in EDTA plasma at Fürst Medical Laboratory using routine methods 139 
(Oslo, Norway).  140 
 141 
Assessment of fat mass 142 
Subjects wore light clothing and no shoes. Two trained persons performed all measurements, 143 
which were performed once, except for triceps skinfold (TSF), which was measured three 144 
times. Height was measured by a wall-mounted stadiometer to the nearest 0.1 cm. Weight was 145 
measured by a Tanita scale (BC-418 MA, Tanita Corp., Tokyo, Japan) to the nearest 0.1 kg. A 146 
correction factor of −1 kg was used to adjust for the weight of light clothing before BMI was 147 
calculated. Waist- and hip circumferences were measured by a standard, non-stretch tape to 148 
the nearest 0.1 cm while standing in a relaxed position with normal respiration. Waist 149 
circumference was measured at a point midway between the iliac crest and the lower rib 150 
margin. Hip circumference was measured as the maximum circumference of the posterior 151 
buttocks and the anterior symphysis. The waist-hip ratio was calculated as waist 152 
circumference/hip circumference and the waist-height ratio was calculated as waist 153 
circumference/height. TSF was measured by using a Harpenden Caliper and a standard, non-154 
stretch tape on the non-dominant arm. The midpoint of the arm was measured, with the 155 
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measuring tape between the shoulder (acromion) and the elbow (olecranon) while the person 156 
was bending the arm 90 degrees. TSF and the mid-upper-arm circumference (MUAC) were 157 
measured at this midpoint. The mid-upper-arm muscle circumference (MUAMC) was 158 
calculated with the equation MUAC- (π x (TSF/10)) = MUAMC (cm) (2).     159 
Body composition was estimated using the single frequency bioimpedance analyzer  160 
Tanita scale, operating at 50 kHz, with eight-point contact electrodes (16). The electrode 161 
arrangement in the system allows separate measurements for each arm and leg, the trunk, and 162 
whole body. Fat mass (% and kg) were calculated from the measured resistance values, 163 
height, body weight, sex, age, and standard body type (defined in the producer`s manual as 164 
less than ten hour of exercise per week). Measurements were performed with the subjects 165 
standing barefoot on the platform with arms slightly apart from the body.  166 
 167 
Statistical analysis 168 
Normality distribution was assessed by looking at the QQ-plots and the distribution of the 169 
histograms of the variables. Descriptive statistics were used. Independent samples t-test was 170 
used for comparison between groups. Univariate linear regression analyses were applied to 171 
quantify the relationship between BIA- and anthropometric measurements of body fat. 172 
Variables with P-values < 0. 2 were included in the multivariate model. A stepwise model 173 
reduction procedure was applied, where the F-ratio test was used. In this test we step-by step 174 
eliminated the non-significant variables from the multivariate model. This was done to 175 
compare the results with and without the non-significant variables. The reduction (elimination 176 
of non-significant variables) was done until it was not possible to reduce the model any 177 
further. Although the groups were matched for age and sex, we adjusted for these variables to 178 
correct any mistakes done in the matching procedure. In order to analyse insulin resistance 179 
markers, lipids and inflammatory markers concentration with respect to body fat, hip 180 
 8 
circumference, BIA measures of fat percent and BMI were divided into tertiles and analyzed 181 
with ANOVA. Sample size calculations were not performed because of the descriptive 182 
design. Statistical significance was set as P< 0.05. The PASW 18 was used for all statistical 183 




Forty-seven (33 men and 14 women) overweight (BMI 25-40 kg/m
2
) whereof 25 were obese 188 
(BMI > 30 kg/m
2
), and 40 lean (BMI 20-25 kg/m
2
) subjects (26 men and 14 women) were 189 
included. The overweight group had an age range from 37 to 68 years, and the lean from 36 to 190 
65 years (Table 1). The data was normally distributed.  191 
 192 
Insulin resistance markers and lipids  193 
Overweight subjects had higher (P<0.05) levels of all insulin resistance markers (insulin, 194 
Homeostasis Model Assessment (HOMA), C-peptide, HbA1c) than their lean counterparts. 195 
Glucose was elevated (P = 0.03) in overweight men relative to the lean ones, but this was not 196 
found among the women (Table 1).  197 
No significant differences in the plasma concentration of total cholesterol were found 198 
between the overweight and lean subjects, but the LDL-cholesterol and triglyceride levels 199 
were higher (P<0.05) whereas the HDL-cholesterol level was lower (P<0.05) in the 200 
overweight relative to the lean subjects (Table 1). 201 
 202 
Inflammatory markers and adipokines  203 
The overweight subjects had higher (P<0.05) levels of CRP and IL-6 than their lean 204 
counterparts. Overweight subjects also had elevated (P<0.05) levels of the leptin and resistin, 205 
compared to the lean subjects, while the level of adiponectin was lower (P<0.05). Overweight 206 
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women had higher levels of CRP than overweight men (P = 0.05) (Table 2). and women in 207 
both groups had higher (P<0.05) levels of leptin and adiponectin than men (Table 2). No 208 
significant difference in plasma levels of IGF-1 was observed.  209 
 210 
Body composition in overweight and lean subjects 211 
All body composition measures were significantly elevated in overweight compared with lean 212 
subjects. Both overweight and lean women had higher TSF (P<0.001), whole body fat (%) 213 
(P<0.01) and fat mass (P<0.01) than their male counterparts (Table 3). Males had higher 214 
levels for all other measurements than females except for hip circumference, mid upper arm 215 
circumference and trunk fat mass.  216 
 217 
Prediction of fat mass  218 
To quantify the relationship between anthropometric estimates of fat mass and body fat 219 
measured with BIA we performed multiple linear regression analyses (Table 4). Hip 220 
circumference had the highest standardized coefficient and explained most of the variation in 221 
whole body- and trunk fat mass (% and kg) in both overweight and lean subjects. Waist-to-hip 222 
ratio demonstrated the second highest standardized coefficient for whole body fat mass        223 
(% and kg) and trunk fat (%) in overweight subjects. In lean subjects, TSF had the second 224 
highest standardized coefficient for all BIA measures of fat mass. In summary, the results 225 
showed that measurements of hip circumference were highly associated with whole body- and 226 
trunk fat mass expressed in kg and percentage, in both lean and overweight subjects. The 227 
results also indicated that an increase in hip circumference with one cm in both overweight 228 
and lean subjects corresponded to an increase in the trunk body fat mass with  229 
360 g.  230 
 231 
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Relationship between insulin resistance markers, lipids and inflammatory markers, and 232 
body fat  233 
Because measurements of hip circumference were closely related to BIA-derived fat mass in 234 
both lean and overweight subjects, tertiles of hip circumference and whole body fat (%) were 235 
used to analyse the relation between fat mass and markers of insulin resistance, lipids and 236 
inflammatory markers (Tables 5 and 6). We also divided BMI into tertiles and performed the 237 
same analysis (Table 7).  238 
In overweight subjects, IL-6 was reduced across tertiles of hip circumference  239 
(Table 5). Levels of adiponectin and leptin increased, while resistin decreased. There was also 240 
an elevation of IGF-1 and CRP concentrations. Levels of HOMA (P<0.05) and C-peptide 241 
(P<0.05) increased and an elevation of triglyserides was seen, while HDL cholesterol 242 
remained stable (Table 5). The same trends were found regarding tertiles of BMI in the 243 
overweight subjects, except for a significant decrease of resistin (P<0.05) and elevated C-244 
peptide (P<0.01) levels (Table 7). Across tertiles of whole body fat (%) (Table 6), there were 245 
also increasing trends in adiponectin (P<0.01) and leptin (P<0.01), IGF-1, CRP, HOMA, and 246 
C-peptide. Concentrations of IL-6 and resistin (P<0.05) increased across tertiles, and 247 
triglyceride concentrations decreased. 248 
Regarding the relation to tertiles of hip circumference in lean subjects (Table 5), IL-6 249 
and adiponectin were reduced, and leptin (P<0.01) and resistin values were increased. Levels 250 
of IGF-1, CRP, HOMA, C-peptide and triglycerides were increased, while HDL cholesterol 251 
was reduced. Similar trends were found for tertiles of BMI in the lean subjects, except for 252 
resistin which was decreased across tertiles, and CRP (P<0.05), which was significantly 253 
increased (Table 7). Like for the tertiles of hip circumference and BMI, leptin (P<0.01), IGF-254 
1, CRP, HOMA and C-peptide, increased across tertiles of fat (%) (Table 6). IL-6 values 255 
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however were stable and resistin (P<0.05) and triglycerides decreased, while HDL cholesterol 256 




































Obesity increases the risk of chronic diseases and the total amount of fat and its distribution 292 
are possibly the most important determinants of these disorders (3). Hip circumference was 293 
found to be the anthropometric measure that best reflected whole body fat (%) and trunk fat 294 
(%) as measured with BIA, in both lean and overweight subjects. Interestingly we found a 295 
tendency towards higher concentrations of leptin, CRP, and C-peptide, as well as adiponectin 296 
and HDL, with higher fat (%), also in subjects with a BMI within the recommended range.  297 
In this study we related frequently used anthropometric measures (BMI, TSF, waist 298 
and hip circumference, waist-to-height, waist-to- hip ratio) to fat mass assessed by BIA. 299 
Several studies have validated BIA by using DXA (15). In comparison with DXA, BIA tends 300 
to overestimate fat mass (% and kg) in lean individuals and underestimate fat mass in obese 301 
(17). Despite these limitations BIA is considered an acceptable tool for predicting body fat in 302 
healthy populations (11). A recent study also demonstrated that BIA correlated significantly 303 
with anthropometric measurements (18). This is in accordance with our study as we found 304 
that TSF correlated significantly with BIA measures of fat (% and kg) in lean subjects and 305 
waist circumference correlated with BIA-measures of fat in overweight subjects. Hip 306 
circumference reflected BIA-measured fat in both groups. 307 
In obesity the fat tissue produces adipokines (19) and cytokines, which may result in 308 
chronic inflammation (20). It has been shown that systemic inflammation is higher in obese 309 
than in normal-weight persons (21). Leptin is preferentially secreted by subcutaneous adipose 310 
tissue (22), and the concentration is dependent on adipocyte size (23) as well as energy 311 
balance (21). In our study we found a strong association between hip circumference and 312 
whole body fat (%), and leptin levels. The same association was also found with BMI. 313 
Normally, leptin levels are higher in obese individuals as demonstrated here. Interestingly we 314 
observed that leptin levels increased with increasing fat (%) also in the lean group. One could 315 
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argue that this could be an effect of food intake or macrophage infiltration in adipose tissue 316 
due to weight gain, which is known to produce higher leptin levels. However, in both study 317 
groups the blood levels were measured during fasting and all subjects reported stable weight 318 
for at least two months prior to inclusion. Few studies have shown the same trend with leptin 319 
levels in lean people, but a positive association between fat mass accumulation, oxidative 320 
stress indices and leptin levels has been observed (7), suggesting that fat mass-induced 321 
oxidative stress may cause a dysregulation of adipokines, also in lean subjects.  322 
A positive relationship between BMI, waist circumference and CRP has been 323 
documented (24). This is in accordance with our study as we found that CRP increased with 324 
increasing BMI and interestingly, this positive relationship was significant in lean subjects. 325 
We also found an association between hip circumference and whole body fat (%) and CRP, 326 
although not significant. These results confirm the findings by Arner et al (25) of an 327 
association between inflammation and fat mass in lean individuals. There is also evidence that 328 
IL-6, a key determinant of CRP production in hepatocytes, is secreted in proportion to the 329 
expansion of fat mass, particularly in the abdominal region (26). We did, however, not detect 330 
stronger associations with CRP and trunk fat mass than with other fat measures. Other adipose 331 
tissue depots in ectopic sites (liver, heart, skeletal muscle) may contribute to the production of 332 
inflammatory mediators in the absence of obesity (27).  333 
Chronic inflammation promotes insulin resistance and cardiovascular disease (5). Our 334 
results show an increase in HOMA and C-peptide as hip circumference and BMI increased, 335 
and an elevation of these markers from the lowest to the highest tertile of whole body fat (%) 336 
in both groups. Low level of HDL-cholesterol is an important risk factor for cardiovascular 337 
disease (28). One would expect a reduction in HDL-cholesterol as fat mass expands. This was 338 
found in our study with increasing hip circumference in lean individuals and with increasing 339 
BMI in both groups. In the overweight however, we found stable levels of HDL-cholesterol as 340 
 14 
hip circumference increased, and elevated levels of HDL-cholesterol from the lowest to 341 
highest tertile of whole body fat (%). Elevated HDL-cholesterol levels were followed by an 342 
inverse reduction of triglyceride levels. Studies have described a subset of obese individuals, 343 
termed metabolically healthy, which appear to be resistant to the development of metabolic 344 
disturbances (29). They have high fat mass and high BMI and high HDL, but low 345 
triglycerides and visceral fat and normal insulin sensitivity. In our study a subgroup of the 346 
overweight people, namely those with BMI > 30 kg/m², but no elevated HOMA, triglyceride- 347 
or LDL levels, had the highest levels of whole body fat (%). It should be noted that all the 348 
overweight women in our study were in the highest tertile of fat (%). This may also explain 349 
our findings regarding adiponectin: In the overweight group we found elevated levels of 350 
adiponectin in the highest tertiles of hip circumference, whole body fat (%) and BMI. Earlier 351 
studies show a decrease (30) in adiponectin levels as fat mass accumulates and an elevation 352 
with weight loss (27).  353 
The major strength of our study is that we examined a broad range of anthropometric 354 
measures. Our study has some limitations since we used indirect measurements as indicators 355 
of total and central fatness. It is therefore difficult to determine exactly the relative 356 
contributions of subcutaneous versus visceral fat. The number of subjects was relatively low 357 
and the results should be confirmed in a larger population. The age and gender heterogeneity 358 
is also a limitation, although the variable was adjusted for.  359 
In conclusion, we have showed that measurements of hip circumference to assess total 360 
body and trunk fat (%) may represent a valid substitute to BIA measurements in both lean and 361 
overweight subjects. Thus this is a highly feasible method outside the hospital setting in order 362 
to identify people at risk of increased inflammation and insulin resistance.  363 
Our results may also suggest that fat (%) is associated with elevation of risk factors for 364 
lifestyle related disorders among lean persons. Although the choice of fat measure may 365 
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impact on the magnitude of these associations, adherence to a healthy lifestyle is also 366 
important for people within the recommended range of BMI. The relationship between 367 
markers of inflammation, insulin resistance and lipids in lean as well as overweight subjects 368 
should be studied further in order to understand the role of fat mass in healthy subjects with 369 
different BMI. Such knowledge may be of considerable interest for early identification of 370 
subjects at risk of type 2 diabetes and cardiovascular disease.  371 
 372 
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